Welcome to our dedicated page for Cvs Health SEC filings (Ticker: CVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CVS Health Corporation filings document formal disclosures for a NYSE-listed health care company with retail pharmacy, pharmacy benefit management, health insurance, clinic, specialty pharmacy, and consumer wellness operations. Recent Form 8-K reports furnish quarterly and annual operating results, financial guidance, investor-day materials, and material events tied to business performance.
The company's proxy materials and other filings describe board composition, director independence, committee assignments, executive compensation, stockholder voting matters, and governance practices. Additional 8-K disclosures record board leadership changes, common-stock registration information, and Omnicare subsidiary chapter 11 proceedings and related financing disclosures.
CVS Health executive vice president and chief financial officer Brian Newman reported a routine tax-related share disposition. He surrendered 2,478 shares of common stock at $90.98 per share to cover withholding taxes due when a restricted stock unit award vested and settled. After this non-market transaction, he continues to hold 3,008 CVS shares directly.
CVS Health Corp executive Amy Compton-Phillips reported a tax-related share disposition tied to equity compensation. On the reported date, 7,618 shares of CVS common stock were surrendered to cover withholding taxes due when a restricted stock unit award vested and settled.
These shares were not sold in an open-market transaction but used as payment of tax obligations. After this tax-withholding event, Compton-Phillips directly owned 9,557 shares of CVS common stock.
CVS Health director Fernando Aguirre reported returning shares of common stock to the company. On May 20, he disposed of 30,437 shares of CVS common stock to the issuer at a weighted average price of $93.775 per share. On May 21, he disposed of an additional 1,563 shares to the issuer at a weighted average price of $93.501 per share, with individual trades that day ranging between $93.50 and $94.01 per share. After these transactions, he directly held 10,513 CVS shares, and no derivative securities were reported in this filing.
CVS submitted a Form 144 notice reporting an intended sale of 32,000 shares of Common Stock in connection with compensation, with the sale date shown as 11/20/2025. The filing lists brokers and numeric entries including 05/20/2026.
CVS Health Corporation filed a shelf registration statement on May 22, 2026 to offer debt securities from time to time after the registration statement becomes effective. This prospectus provides a general description of potential senior or subordinated debt securities; specific terms, amounts and pricing will be provided in prospectus supplements.
The prospectus describes covenants, events of default, remedies, limitation on secured funded debt and sale/leaseback transactions, global security mechanics, and legal and tax defeasance provisions. Net proceeds, unless otherwise specified in a supplement, will be used for general corporate purposes.
CVS Health Corp director-associated funds reported sizable open-market sales of CVS stock and related derivatives. Investment funds managed by Glenview Capital Management sold a total of 3,750,000 CVS-related shares, including common stock and cash-settled swaps referencing common shares, over May 19–21, 2026 at weighted average prices in the mid-$90s per share.
The transactions were executed indirectly through the Glenview Investment Funds and the GO Fund, not by Larry Robbins personally. Following these sales, entities managed by Glenview Capital Management continued to hold 4,824,799 CVS common shares indirectly, while the cash-settled swap position referencing 378,000 shares was reduced to zero.
CVS Health Corp director-associated funds reported sizable open-market sales of CVS stock and related derivatives. Investment funds managed by Glenview Capital Management sold a total of 3,750,000 CVS-related shares, including common stock and cash-settled swaps referencing common shares, over May 19–21, 2026 at weighted average prices in the mid-$90s per share.
The transactions were executed indirectly through the Glenview Investment Funds and the GO Fund, not by Larry Robbins personally. Following these sales, entities managed by Glenview Capital Management continued to hold 4,824,799 CVS common shares indirectly, while the cash-settled swap position referencing 378,000 shares was reduced to zero.
CVS Health Corporation reported results from its May 14, 2026 Annual Meeting of Stockholders. Shareholders approved the new 2026 Incentive Compensation Plan, which will govern awards granted after May 14, 2026 and replaces the expiring 2017 plan.
All 13 director nominees were elected for one-year terms. Shareholders also ratified Ernst & Young LLP as independent auditor for 2026 and approved, on an advisory basis, executive compensation as described in the proxy statement. A stockholder proposal to reduce the threshold for acting by written consent did not pass. A quorum was present, with 1,142,802,406 common shares represented.
CVS Health Corp director John E. Gallina received 1,447.5039 deferred stock units on May 14, 2026. The units were issued as a semi-annual retainer under the company’s non-employee director compensation policy, valued at $97.15 per unit, and each unit will convert into one share of common stock at a future time he elects.
CVS Health Corp director Michael F. Mahoney reported receiving a grant of deferred stock units as part of his non-employee director compensation. On May 14, 2026, he was awarded 1,737.0046 deferred stock units, valued at $97.15 per unit, for deferral of a semi-annual retainer under the company’s 2017 Incentive Compensation Plan.
Each deferred stock unit is scheduled to convert into one share of CVS common stock and be issued in the future, according to his election. After this grant, Mahoney holds a total of 6,428.8174 deferred stock units directly, reflecting routine, compensation-related equity accrual rather than an open-market purchase or sale.